J&J stops schizophrenia trial early on interim efficacy

Johnson & Johnson (NYSE:JNJ) stopped early a 509-patient Phase III trial evaluating a three-month formulation of Invega Sustenna paliperidone palmitate to treat schizophrenia after an interim analysis showed the product met the primary endpoint of delaying time to first relapse vs. placebo. The interim analysis was conducted after 42 events, or 60% of projected relapses, occurred. ...